Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal year 2026. BMS and Hengrui signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal 2026. Daiichi Sankyo aims to be a global top-5 oncology player while expanding beyond antibody-drug conjugates. Plus more. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation…

Source: FiercePharma